{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071382","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.941954+00:00","generated_at":"2026-05-21T11:17:30.636614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenax Therapeutics Q1 net loss $10.4M; Phase 3 LEVEL enrollment on track for year-end 2025","bullets":["Net loss $10.4M in Q1 2025 vs $3.8M in Q1 2024; company is a development-stage biotech with no revenue.","Cash and equivalents $111.4M as of March 31, 2025; raised ~$25M gross proceeds from private placement in March 2025.","Phase 3 LEVEL study enrollment of 230 patients in PH-HFpEF targeted for completion around year-end 2025; topline data mid-2026.","Initiation of second registrational Phase 3 study (LEVEL-2) for TNX-103 expected in 2025.","R&D expense $5.7M (up from $2.7M) and G&A $5.7M (up from $1.2M) due to trial costs and stock-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071382","json":"https://secwatch.observer/filing/0000950170-25-071382.json","markdown":"https://secwatch.observer/filing/0000950170-25-071382.md","text":"https://secwatch.observer/filing/0000950170-25-071382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000095017025071382/0000950170-25-071382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000095017025071382/tennx-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T11:17:30.636614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}